LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition
Open Access
- 22 January 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 100 (2), 370-375
- https://doi.org/10.1038/sj.bjc.6604886
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- The LKB1 tumor suppressor negatively regulates mTOR signalingCancer Cell, 2004
- Regulation of B-Raf Kinase Activity by Tuberin and Rheb Is Mammalian Target of Rapamycin (mTOR)-independentOnline Journal of Public Health Informatics, 2004
- Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndromeGenes & Development, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004
- LKB1 Kinase: Master and Commander of Metabolism and PolarityCurrent Biology, 2004
- MO25 / interact with STRAD / enhancing their ability to bind, activate and localize LKB1 in the cytoplasmThe EMBO Journal, 2003
- Management of cellular energy by the AMP‐activated protein kinase systemFEBS Letters, 2003
- A serine/threonine kinase gene defective in Peutz–Jeghers syndromeNature, 1998
- The modular phosphorylation and activation of p70s6kFEBS Letters, 1997